Compare ACRS & CCNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACRS | CCNE |
|---|---|---|
| Founded | 2012 | 1865 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.5M | 1.0B |
| IPO Year | 2015 | 1995 |
| Metric | ACRS | CCNE |
|---|---|---|
| Price | $5.17 | $33.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $10.20 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 2.4M | 110.5K |
| Earning Date | 05-07-2026 | 04-20-2026 |
| Dividend Yield | N/A | ★ 2.51% |
| EPS Growth | ★ 69.01 | 4.18 |
| EPS | N/A | ★ 1.79 |
| Revenue | ★ $1,683,000.00 | N/A |
| Revenue This Year | N/A | $23.21 |
| Revenue Next Year | $4.24 | $7.00 |
| P/E Ratio | ★ N/A | $18.94 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.74 | $22.90 |
| 52 Week High | $6.60 | $36.17 |
| Indicator | ACRS | CCNE |
|---|---|---|
| Relative Strength Index (RSI) | 39.06 | 50.66 |
| Support Level | $4.99 | $34.07 |
| Resistance Level | $5.87 | $35.17 |
| Average True Range (ATR) | 0.36 | 0.65 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 15.38 | 45.33 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
CNB Financial Corp is a Pennsylvania-chartered bank. The bank is a full-service bank engaging in a full range of banking activities and services for individual, business, governmental and institutional customers. These activities and services principally include checking, savings, and time deposit accounts; real estate, commercial, industrial, residential and consumer loans; and a variety of other specialized financial services. Its Private Client Solutions division offers a full range of client services, including private banking and wealth and asset management. The banking segment derives its revenue through the operations as a full-service bank services, including trust and wealth management services, for individual, business, governmental, and institutional customers.